All Industries

Atlantic Lithium sees potential for big resource expansion at Ewoyaa after extension drilling

Atlantic Lithium Limited

Atlantic Lithium Ltd Chief Geologist and Head of Business Development Len Kolff joined Proactive's Stephen Gunnion with details of more high-grade intersections that were revealed during extension drilling outside of the confirmed resource area at its Ewoyaa project in Ghana. Speaking from Cape Town during the Mining Indaba, Kolff said there is potential to significantly expand the lithium resource beyond the current 35.3 million tonne estimate. These results include the longest intercept from the 2023 drilling program, featuring an 83-metre section with 1% lithium oxide, located outside the previously confirmed resource area. Kolff expressed optimism about updating the resource estimate by the second or third quarter of this year, pending further assay results from the 2023 drilling program and completion of planned drilling activities. For 2024, the priority remains on enlarging the resource base to support the development of the Ewoyaa project while assisting the mine build team with necessary sterilisation drilling around proposed plant sites. Contact Details Editorial +44 20 7989 0813 uk@proactiveinvestors.com Company Website https://www.proactiveinvestors.co.uk

February 06, 2024 11:38 AM Eastern Standard Time

Video

BP rallies on share buyback plan; focus turns to volatility around Uber and PayPal - OptionsDesk

Options Desk

OptionsDesk's Sebastian Blanco joined Proactive's Stephen Gunnion with a preview of quarterly earnings on Wednesday from Uber and PayPal. Following a strong rise in Uber's share price last year, Blanco said meeting expectations won't be enough for Uber; unless it beats expectations its shares could come under pressure. PayPal's shares are down over the past year as it faces increasing competition in the payments space and investors will watch its results keenly to see how it is addressing this. Blanco also commented in a surge in BP's share price after it released better-than-expected profits and details of a significant share buyback program. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 06, 2024 10:29 AM Eastern Standard Time

Video

Salus GRC Hires Alan Knepfer as Chief Revenue Officer

Salus GRC

Salus GRC recently welcomed Alan Knepfer as Chief Revenue Officer. Reporting to Chief Executive Officer William Mulligan, Mr. Knepfer is responsible for leading Salus GRC’s global revenue operations, with a focus on driving sales and marketing excellence and identifying strategic growth initiatives. He joins Salus GRC during an impressive period of growth. Amassing clients with over $200B in AUM over the past two quarters alone, Salus GRC has also created a collective of talented, deeply experienced, and highly respected resources in the field, with the singular mission of providing unparalleled service. Salus GRC provides a full suite of tech-enabled Governance, Risk and Compliance (“GRC”) support to private fund managers and other financial services firms, with offerings that include regulatory registration and filing services, compliance program development and ongoing support, regulatory exam assistance, compliance training and education, regulatory due diligence, and cybersecurity. Salus GRC aspires to be the employer of choice in the GRC space, attracting experienced professionals who bring a singular focus on providing the highest level of client service. Over time, Salus GRC expects to expand its service offering to include ESG, regulatory technology (RegTech), and GRC support for other industry verticals. Mr. Knepfer brings over 25 years of experience leading, building, and reinventing scalable revenue organizations. Most recently he was the Chief Revenue Officer at RadarFirst, a Privacy Incident Management software provider. In addition, he has held numerous senior management positions including President and Chief Revenue Officer of Comodo Cybersecurity and Global Head of Sales and Customer Success at NASDAQ. “I am thrilled to welcome Alan as our Chief Revenue Officer and member of the Executive Management Team,” said Mr. Mulligan. “With a proven track record of achieving exceptional results and building sustainable, profitable businesses, Alan is the right visionary leader to join our great team in helping drive our next phase of strategic growth at Salus GRC. His passion for Customer Success and Marketing will be invaluable as we continue to help clients maximize our tech-enabled solutions.” “Salus GRC is uniquely positioned to capitalize on a fragmented market in search of a leader,” said Mr. Knepfer. “I’m thrilled to join this experienced team of industry superstars – who have each built an incredible following in this space – and to combine our efforts towards building the leading tech platform for GRC services. Our people and our collective focus are a powerful combination, positioning us well for years of growth, at an accelerated rate rarely seen in any business.” About Salus GRC: Launched in the Spring of 2023, in partnership with financial sponsor Charlesbank Capital Partners, Salus GRC provides GRC services to private fund managers, registered investment advisers, CFTC-registered managers, and broker-dealers. Offerings include regulatory registration and filing services, compliance program development and ongoing support, regulatory exam assistance, compliance training and education, and regulatory due diligence. About Charlesbank Capital Partners: Based in Boston and New York, Charlesbank Capital Partners is a middle-market private investment firm with more than $17 billion of capital raised since inception. Charlesbank focuses on management-led buyouts and growth capital financings, and engages in opportunistic credit and technology investments. The firm seeks to build companies with sustainable competitive advantage and excellent prospects for growth. For more information, please visit www.charlesbank.com. Contact Details Salus GRC Monique Stehle mstehle@salusgrc.com Charlesbank Ryan FitzGibbon / Dan Ivers / Peter Gavaris pro-charlesbank@prosek.com Company Website https://www.salusgrc.com/

February 06, 2024 10:15 AM Eastern Standard Time

Image

Prodigy Biotech Enters into a Partnership Agreement with Leading Cancer Center to Advance Products to Improve Outcomes in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Prodigy Biotech

Prodigy is the first company to join the MSK Therapeutic Accelerator. The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024. Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will co-develop a product targeting Enterococcus sp. to treat microbial dysbiosis in patients undergoing allogenic hematopoietic stem cell transplantation. The product will be built on Prodigy’s polyclonal Immunoglobulin Y (IgY) technology that has shown promising preclinical data in models of alcoholic liver disease. Prodigy and MSK have entered into a sponsored research agreement through the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate for the improvement of outcomes in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HCT). The MSK Therapeutic Accelerator project will be led by Jonathan Peled, MD, PhD, Assistant Attending Physician, MSK. Through his pioneering research, Dr. Peled and his team at MSK have significantly advanced the role of the microbiome in impacting outcomes in patients undergoing allo-HCT. Dr. Peled’s work revealed that patients undergoing allo-HCT have enterococcal domination events and these domination events lead to worse overall survival and higher graft vs. host disease (GvHD)-related mortality. Dr. Peled has previously demonstrated in preclinical models that resetting the gut microbiome has profound outcomes in mitigating disease severity. In this collaboration, Prodigy’s Enterococcus sp. neutralizing antibodies will be evaluated in preclinical models of GvHD and product candidates will be developed to move into clinical development. Furthermore, Prodigy is pleased to have Dr. Peled join and help build its allo-HCT Scientific Advisory Board (SAB). In addition to the sponsored research, MSK will provide expertise and institutional resources through the MSK Therapeutics Accelerator to aid in the development of a drug candidate for patients undergoing allogenic hematopoietic stem cell transplantation. MSK’s Therapeutic Accelerator Program is a partnership program between MSK and technology and pharmaceutical companies to advance novel therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK’s community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on treatment or management of cancer. Satish Chandran, CEO of Prodigy said, “ We are delighted to collaborate and partner with MSK’s Therapeutic Accelerator Program and Dr. Peled to develop product(s) for patients undergoing allo-HCT. Given the significant morbidity and mortality associated with the disease, it is incumbent upon all of us to find solutions that have the potential to save lives and restore normalcy to these patients. We have been very pleased with the robust preclinical proof-of-concept data of our product PROD-AH-001, (Hepatology, 2023) for alcoholic hepatitis which is currently being readied for an IND submission with the FDA.” Dr. Jonathan Peled of MSK said, "Patients who are treated with allo-HCT experience the most extreme microbiome injuries observed in any clinical setting. There is an urgent need to develop approaches that can mitigate this and prevent the expansion of potentially pathogenic bacteria. We hypothesize that attenuating the expansion of Enterococcus within the gastrointestinal tract will prevent bloodstream infections with this bacterium and potentially also ameliorate GVHD.” Dr. Chandran presented information about this important new collaboration at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024. About Allogenic Hematopoietic Stem Cell Transplantation Allo-HCTs have a chance to cure malignancies but are associated with high rate of complications and mortality. Allo-HCT can lead to various complications, affecting different organs due to the intense conditioning regimen and introduction of foreign immune cells. A significant concern after allo-HCT is graft-versus-host disease (GvHD), where the donor's immune cells mount an attack against the recipient and is a major cause of morbidity and non-relapse mortality in this patient population. There is a clear need of therapies that are able to improve outcomes in patients undergoing allogenic hematopoietic stem cell transplantation. About Prodigy Biotech, Inc. Prodigy Biotech is a privately held biopharmaceutical company focused on developing products using its polyclonal Immunoglobulin Y technology to selectively edit the microbiome while avoiding deleterious effects to the commensal microflora. The versatility of avian antibodies, IgY, allows for pathogen- specific neutralization capabilities not only to bacteria but also viruses, fungi, endotoxins, and even human secreted proteins such as cytokines and chemokines. A target agnostic approach and strategic collaborations with leading researchers in the microbiome field has allowed Prodigy to build a diverse pipeline ranging from modulating the gut microbiome in alcoholic liver disease (ALD) to modulating the lung microbiome in chronic obstructive pulmonary disease (COPD). Cautionary Note on Forward-Looking Statements: This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Contact Details Prodigy Biotech, Inc. Satish Chandran satish.chandran@prodigybiotech.com Company Website https://www.prodigybiotech.com/

February 06, 2024 10:00 AM Eastern Standard Time

GoGlobal Announces International Business Expansion Expert Sissi Zhao as New Partner

GoGlobal

GoGlobal, a leading firm specializing in international business expansion services, recently announced the appointment of Sissi Zhao as a Partner, effective February 1st, 2024. This strategic move comes as part of the company’s ongoing efforts to enhance its leadership team and expand its global footprint, particularly in the fast-growth Asia Pacific (APAC) region. Sissi Zhao, a seasoned professional with an illustrious career in international business expansion, law, private equity and mergers & acquisitions, brings a wealth of knowledge and diversified insight to GoGlobal. Since joining GoGlobal, Sissi has played a pivotal role in the expansion of the company’s business operations in Asia. Her adept management of both inbound and outbound expansion opportunities has significantly contributed to the firm’s thriving success across the APAC region. Sissi's strategic foresight and deep understanding of the business landscapes in both Europe and APAC, bolstered by 12 years of living in Europe facilitating cross-border transactions and her six years’ onsite working experiences in Asia, equip her with an unparalleled ability to guide clients eyeing the dynamic Europe-Asia corridor for business expansion. "I am thrilled to step into this role and am committed to further propelling GoGlobal's growth. Our focus remains on closely collaborating with visionary companies eager to tap into the vast opportunities across the world. I am excited to leverage my expertise and facilitate our clients' expansion endeavors in today's dynamic and ever-evolving global economy,” says Sissi. "We congratulate Sissi on her well-deserved appointment and look forward to her contributions in shaping the future of GoGlobal," says Margaret Yip, Partner at GoGlobal. "Her exceptional skills and dedication are invaluable to our mission of facilitating seamless global expansion for our clients." About GoGlobal GoGlobal is a people-first international HR and Employer of Record (EOR) service provider, with a globally distributed, naturally diverse remote workforce. GoGlobal's technology enabled EOR solution allows companies of all sizes to hire people anywhere in the world without the need to set up a local entity, opening new doors to rapid expansion and growth. With a presence in over 137 countries on six continents and growing, GoGlobal helps clients recruit, hire, manage and pay exceptional talent – quickly, cost effectively and compliantly. Contact Details GoGlobal Bonnie Elgie +1 403-630-6164 bonnie.elgie@goglobalgeo.com

February 06, 2024 09:51 AM Eastern Standard Time

Wormhole Foundation Awards Contributor Grant to Zpoken to Advance Trustless ZK Transfers for NEAR and Ethereum

Wormhole Foundation

The Wormhole Foundation, a research and development organization dedicated to interoperability between blockchains, is excited to announce a Contributor Grant to the team at Zpoken. The addition of the Zpoken team to Wormhole’s decentralized set of contributors is a major step forward for Wormhole's platform in the context of trustless verification of cross-chain messages using Zero Knowledge (ZK) technology. Zpoken has established itself as a key player in the field of ZK technology globally, notably with its work on the NEAR ZK Light Client. Wormhole’s capabilities will include the first trustless, zero knowledge Ethereum-to-NEAR corridor. This bi-directional bridge will enable all major NEAR and Ethereum-based assets to be transferred across chains without needing to trust any centralized actors for message verification, despite Wormhole currently having the most trusted set of decentralized validators ( see Uniswap’s Bridge Assessment ), the Wormhole Guardians. Given Wormhole’s modular and flexible technology stack, Wormhole Guardians will continue to verify messages for any corridor not yet integrated with ZK proofs. Robinson Burkey, Co-founder and Chief Commercial Officer at Wormhole Foundation, remarked, "Offering our developer community trustless verification for their messages between Ethereum and NEAR will be a major milestone. The Foundation is very excited to add Zpoken to the decentralized team of collaborators and the integration of their ZK technology into Wormhole's interoperability platform, and we look forward to rolling this technology out to developers." Mike Yezhov, CEO at Zpoken added, “Integrating cryptographic commitments into economic models to enhance the interoperability of the decentralized web is an incredibly exciting endeavor. We are thrilled to contribute our expertise in NEAR Zero-Knowledge light clients to some of the largest and most promising interoperability protocols within the Web3 ecosystem. This contribution represents a significant step forward in securing and streamlining the interaction between diverse blockchain networks, thereby unlocking new possibilities for decentralized applications and services.” For further inquiries and collaboration opportunities, please contact the Wormhole Foundation at hello@wormhole.foundation. About Zpoken Zpoken is a full-stack Web3 development organization that specializes in the development and implementation of ZK technology, cryptography solutions and decentralized tech. Their work on the Near ZK Light Client is instrumental in advancing the field of trustless cross-chain communication, offering a new paradigm of privacy and security in blockchain technology. About Wormhole Foundation The Wormhole Foundation is the steward of Wormhole - the world’s first generalized messaging protocol. Our mission is to empower passionate people in the research and development of blockchain interoperability technologies. Through grants, research, and ecosystem programs, we seek to enable teams to build secure, open-source, and decentralized products within the Wormhole ecosystem. If you’re interested in helping achieve our mission, follow us on Twitter or contact us at hello@wormhole.foundation. Contact Details Ditto PR Wahaj Khan +1 630-935-7684 wahaj@dittopr.co

February 06, 2024 09:02 AM Eastern Standard Time

Doceree Secures Patent for its Groundbreaking Technology Empowering Marketers to Elevate Patient-Physician Engagement Through Real-Time Triggers on EHR Platforms

Doceree

Doceree, the leading global healthcare marketing platform building unprecedented solutions for programmatic HCP marketing using proprietary data tools, today announced the grant of a patent by US Patent and Trademark Office (USPTO) for its distinguished feature ‘Triggers’ that uses clinical data as real-time prompts for messaging to HCPs on Electronic Health Record Platforms, in a HIPAA-compliant and privacy-forward way. In the United States, physicians possess the potential to enhance healthcare delivery by leveraging relevant information; however, the challenge lies in the timely accessibility of crucial data. Despite the ongoing digital transformation in the healthcare sector, Healthcare Professionals (HCPs) continue to face a notable gap in accessing up-to-date information, a resource that is currently exclusive to life sciences organizations. As the industry undergoes rapid digitization, the need for efficient information dissemination to empower healthcare providers becomes increasingly evident. Bridging this information gap, Doceree introduced Triggers- a technological solution designed to guarantee the delivery of optimal and well-informed care to patients. Doceree's groundbreaking patent, officially paves the way for the integration of Doceree Triggers into the pharmaceutical marketing landscape. This patent encompasses a sophisticated medical product processing system that employs a first graphical user interface connected to an Electronic Health Record (EHR) platform. The system is designed to display messages in real-time to medical providers, tailored to their patients' predefined conditions. These conditions are inputted into the patient's electronic health record during the interaction between the patient and the healthcare provider, encompassing crucial details such as definitions of international classifications of diseases (ICD) codes. This patent not only represents a pivotal achievement, affirming Doceree's pioneering strategy in revolutionizing the interaction between pharmaceutical marketing and healthcare professionals, but it also plays a crucial role in aiding Electronic Health Record (EHR) platforms. The patent ensures real-time clinical data mapping in a HIPAA-compliant manner, contributing to the optimization of EHRs for health data interoperability. This optimization holds significant importance in supporting clinical research efforts. The seamless integration of research and clinical care within a health system has the potential to boost clinical trial participation rates, enhance health outcomes, reduce the cost of care, and foster greater patient satisfaction. " This patent not only signifies our steadfast dedication to pushing the boundaries and creating pioneering solutions for addressing the industry's most intricate challenges but also stands as a significant milestone in our journey towards establishing leadership in healthcare innovation and technology," stated Harshit Jain MD, Founder, and Global CEO of Doceree. " Beyond its legal implications, this inaugural patent reflects the resilience and forward-thinking ethos that defines our company. It serves as the bedrock for sustained success in the ever-evolving landscape of innovation, embodying our commitment to continuous advancement. The issuance of this patent is a powerful reminder of what can be achieved through collaborative efforts and a shared dedication to our strategic objectives," he emphasized. Doceree Triggers stands out by offering pharmaceutical manufacturers a distinctive set of capabilities. It enables the strategic planning and coordination of healthcare provider and direct-to-consumer campaigns, leveraging comprehensive insights into patient and provider behaviors, including the evaluation of past and present script performance. The platform empowers users to activate media seamlessly across various channels, encompassing display, video, and connected TV, all while optimizing bids to enhance overall business outcomes. Real-time performance measurement is a key feature, providing immediate insights into each campaign's effectiveness. Moreover, Doceree Triggers facilitates the dynamic optimization of ongoing campaigns by automatically adjusting parameters, enhancing audience quality, boosting script lift, and maximizing overall media efficiency. This multifaceted approach ensures that pharmaceutical marketing efforts are not only well-informed but also agile and responsive, driving impactful results in the competitive landscape. About Doceree: Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) messaging with proprietary data and advanced tools. Utilizing an extensive global network of digital endemic and point-of-care platforms, Doceree facilitates seamless and meaningful communication between life sciences brands and HCPs, ensuring delivery of highly personalized messages to HCPs at scale. To learn more, https://doceree.com/us/doceree-triggers/. Contact Details Doceree Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Doceree Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/doceree-triggers/

February 06, 2024 09:00 AM Eastern Standard Time

Sienna Resources Expands Its Portfolio To Include Two Uranium Projects In The Athabasca Basin Region As Global Prices Hit A 16-Year High

Benzinga

By Faith Ashmore, Benzinga 2024 is off to an interesting start as uranium prices jumped to a 16-year high, a trend that started in mid-2021. After almost a decade of dormancy following the Fukushima nuclear accident, uranium prices have sky-rocketed 250% since 2021, when COVID disruptions started impacting price increases. While resistance to nuclear power still exists, the need to cut commissions and decreased animosity towards nuclear power is partly responsible for the rising demand. However, the growing demand is coupled with a decrease in supply and a wariness to purchase uranium from Russia. Biden has faced scrutiny for continuing the policy of importing uranium from Russia, which accounts for approximately one-third of the uranium used in the U.S. Additionally, other historical producers and supply are being disrupted; Kazakhstan’s lead uranium producer Kazatomprom (OTCMKTS: NATKY) announced recently that it may have to cut production in 2024 due to difficulties with sulphuric acid availability. Uranium suppliers are clearly a hot commodity at the moment. Recognizing this, Sienna Resources Inc. (OTCMKTS: SNNAF), a company focused on exploring and developing mineral resources, has gotten into the uranium market. Sienna Resources has recently expanded its portfolio in the Athabasca Basin of Saskatchewan, adding the "Uranium Town Project" and the "Dragon Uranium Project" to its collection. The Athabasca Basin region is renowned for its rich uranium deposits, and Sienna's acquisitions provide a sizeable land area spanning over 21,000 acres. The Uranium Town Project covers an area of 10,357 acres adjoining ∫ (NYSE: DNN), while the Dragon Uranium Project spans an impressive 10,845 acres bordering Cameco Corporation (NYSE: CCJ) – the world's largest producer of uranium. The Fraser Institute has ranked Saskatchewan as the third-most attractive mining jurisdiction globally, adding to the potential of these newfound projects. Adding these projects bolsters Sienna Resources' presence in the valuable Athabasca Basin region and potentially sets the stage for exciting exploration opportunities, in addition to the company's existing lithium and graphite projects. Jason Gigliotti, President of Sienna shared, “Uranium prices have hit a 16-year high this week and management feels that diversifying into uranium while keeping our lithium focus makes sense. Establishing a large footprint in the most prolific uranium address on the globe bordering the biggest name in uranium, Cameco, provides Sienna and Sienna shareholders with exposure to the best-performing sector in mining in the past year. Management continues to try to add projects that are accretive to the growth of Sienna and we have enough cash on hand to forward these projects.” Uranium is having a moment on the demand side and as the U.S. looks to decrease reliance on Russian importers, companies like Sienna Resources could stand to become industry leaders. Not to mention, uranium’s connection to greener energy makes it a valuable asset in the race to decrease carbon emissions. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:45 AM Eastern Standard Time

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy

Benzinga

By Jeremy Golden, Benzinga A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The data produced by Elicio Therapeutics Inc. (NASDAQ: ELTX) demonstrates how Elicio’s proprietary Amphiphile (AMP) lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell (TCR-T cell) therapies while enhancing anti-tumor function and eradicating solid tumors. According to Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics, optimization of TCR-T cell therapy could potentially have wide-ranging therapeutic benefits in many previously intractable solid tumors. During the study, AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumor microenvironment and led to epitope spreading against diverse tumor targets. Additionally, long-term protection against tumor recurrence in AMP-treated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by the treatment. “In this study, we’ve demonstrated that boosting TCR-T cell therapy directly in the lymph nodes with AMP immunotherapy resulted in durable anti-tumor T cell responses and tumor eradication,” DeMuth said. “The AMP treatment uniquely promoted potent mechanisms for immune activation in lymph nodes to invigorate both adoptive and endogenous anti-tumor T cell immunity. Simple application to a variety of cancer targets including mKRAS, HPV E7 and NY-ESO-1 could elevate existing TCR-T cell therapies to generate powerful new combinations for hard-to-treat solid tumors.” Elicio Therapeutics is developing a pipeline of novel immunotherapies for the treatment of cancer. Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008. Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the lymph nodes, sometimes referred to as the “brain center” of the immune system. In previous Elicio studies, the results found that AMP immunotherapy promoted specific trafficking and retention of payloads into lymph nodes, yielding enhanced T cell numbers, persistence and functional quality. Preliminary phase 1 data from the ongoing study of Elicio’s lead asset, ELI-002, demonstrated significant T cell responses – including both CD4+ and CD8+ – when administered as an adjuvant monotherapy in patients with pancreatic and colorectal cancers. The strength of the T cell response induced by ELI-002, an mKRAS-specific AMP vaccine, was further correlated to significant improvements in tumor biomarker response, along with reduced risk of progression and death. This indicates an association between the ELI-002 mechanism of action and clinical outcome. “This study adds to our growing body of preclinical and clinical evidence demonstrating the importance of the lymph nodes and the robust efficacy that our AMP immunotherapy strategy can potentially achieve for patients with solid tumors, both as a monotherapy and in combination with other strategies,” said Robert Connelly, Chief Executive Officer at Elicio Therapeutics. “The AMP platform provides attractive potential for broad and rapid application to clinical and developmental TCR-T cell programs. We look forward to finding the right partner to advance this promising combination into the clinic for patients with solid tumors.” Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:35 AM Eastern Standard Time

Image

1 ... 442 443 444 445 446 ... 3764

Back